Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TSPO | P30536 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9069782 | 0.81 | POLB (0.48) | MEN1KMT2ALMNATSHRSMN1; SMN2 | |
| SCHEMBL27600746 | 0.81 | TSHR (0.43) | MEN1KMT2AKDM4ELMNAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL29361741 | 0.79 | RAB9A (0.47) | KMT2AKDM4ELMNATSHRTSPO | |
| SCHEMBL26619124 | 0.78 | TRPM8 (0.49) | MEN1KMT2ALMNATSHRSMN1; SMN2 | |
| SCHEMBL2218296 | 0.78 | ALDH1A1 (0.39) | KDM4ELMNAL3MBTL1TSHRSMN1; SMN2 | |
| SCHEMBL30571184 | 0.77 | ALDH1A1 (0.45) | MEN1KMT2ALMNATSHRSMN1; SMN2 | |
| SCHEMBL4699526 | 0.77 | MEN1 (0.53) | MEN1KMT2AKDM4EHSD17B10LMNA | |
| SCHEMBL4996914 | 0.77 | ALDH1A1 (0.45) | MEN1KMT2ALMNATSHRSMN1; SMN2 | |
| SCHEMBL5228241 | 0.76 | MEN1 (0.49) | MEN1KMT2AKDM4EHSD17B10LMNA | |
| Bromide SCHEMBL28268585 | 0.76 | ALDH1A1 (0.44) | MEN1KMT2ALMNATSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9567307-B2 | Amination of aryl alcohol derivatives | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567307-B2 | Amination of aryl alcohol derivatives | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-14 | — | — | US | disclosed |
| US-20130289270-A1 | Amination of Aryl Alcohol Derivatives | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130289270-A1 | Amination of Aryl Alcohol Derivatives | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-31 | — | — | US | disclosed |
| EP-0276204-A2 | Pyridine gametocides | Monsanto Company (US) | 1988-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289270-A1 | Amination of Aryl Alcohol Derivatives | SULT2A1, SULT1A1, ADH5 | MEN1 4461/4885KMT2A 122/4885KDM4E 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.